A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer

NCT03086239 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Rovalpituzumab tesirine

Sponsor

AbbVie